First Tracks Biotherapeutics TRAX
$41.64 −$2.82 (-6.34%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $40.70 -2.26%
Open$43.99
Prev close$44.46
Day range$41.23 – $44.74
Volume504.4K
Market cap$1.75B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$32.84M+27.1% YoY
Net profit-$31.36M+25.1% YoY
Diluted EPS-$0.88+26.9% YoY
Free cash flow-$17.05M+44.5% YoY
Operating cash flow-$17.05M
Revenue, last 6 quarters
Net profit, last 6 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Current ratio9.16
Liabilities / assets11.4%
Cash & investments$155.63M
Total debt$1.36M
Net cash (debt)$154.27M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income (Expense) | -$7,000.00 | -$1,000.00 | -$1,000.00 | – | -$13,000.00 |
| Operating Expense | $32.84M | $34.94M | $52.81M | $45.06M | $45.90M |
| Selling and Admin Expenses | $9.00M | $9.29M | $18.86M | $11.74M | $6.63M |
| -General & Admin Expense | $9.00M | $9.29M | $18.86M | $11.74M | $6.63M |
| Research & Development | $23.85M | $25.64M | $33.96M | $33.32M | $39.27M |
| Operating Profit | -$32.84M | -$34.94M | -$52.81M | -$45.06M | -$45.90M |
| Diluted EPS | -$0.88 | -$0.95 | -$1.45 | -$1.20 | -$1.22 |
| Net Non-Operating Interest Income (Expense) | $1.50M | $1.56M | $2.33M | $3.20M | $3.47M |
| Non-Operating Interest Income | $1.50M | $1.56M | $2.33M | $3.20M | $3.47M |
| Other Non-Operating Income (Expenses) | -$7,000.00 | -$1,000.00 | -$1,000.00 | – | -$13,000.00 |
| Pretax Profit | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M |
| Net Profit | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M |
| Profit from Continuing Operations | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M |
| Net Income to Parent Company | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M |
| Net Income to Common Stockholders | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M |
| Basic EPS | -$0.88 | -$0.95 | -$1.45 | -$1.20 | -$1.22 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2024 ANNUAL | 2023 ANNUAL |
|---|---|---|---|---|---|
| -Common Stock | $36,000.00 | $35,000.00 | – | – | – |
| -Preferred Stock | $0.00 | $0.00 | – | – | – |
| Total Assets | $170.46M | $183.14M | $290.58M | $441.89M | $444.11M |
| Total Current Assets | $165.72M | $177.75M | $289.40M | $389.93M | $398.56M |
| Cash and Cash Equivalents & Short-Term Investments | $155.63M | $168.02M | $286.46M | $385.37M | $390.90M |
| -Cash and Cash Equivalents | $155.63M | $168.02M | $248.47M | $123.08M | $35.97M |
| -Short Term Investments | $0.00 | $0.00 | $37.99M | $262.29M | $354.94M |
| Receivables | $2.87M | $5.07M | – | – | – |
| -Other Receivables | $2.87M | $5.07M | – | – | – |
| Prepaid Assets | $5.22M | $2.47M | – | – | – |
| Other Current Assets | $2.01M | $2.18M | $2.95M | $4.56M | $7.65M |
| Total Non-Current Assets | $4.73M | $5.40M | $1.17M | $51.96M | $45.55M |
| Net PPE | $4.73M | $5.40M | $1.17M | $16.23M | $18.27M |
| -Gross PPE | $12.10M | $12.67M | $8.35M | $22.83M | $24.49M |
| -Accumulated Depreciation | -$7.37M | -$7.28M | -$7.17M | -$6.60M | -$6.22M |
| Additional Paid-In Capital | $206.91M | $193.34M | – | – | – |
| Retained Earnings | -$55.93M | -$24.58M | – | – | – |
| Gains/Losses Not Affecting Retained Earnings | $0.00 | $0.00 | -$146,000.00 | $305,000.00 | -$797,000.00 |
| Short-Term Debt and Capital Lease Obligation | $2.42M | $2.44M | – | $1.93M | $1.78M |
| Current Accrued Expenses | $7.59M | $5.49M | $20.76M | $23.05M | $9.43M |
| -Accounts Payable | $3.95M | $2.55M | $7.50M | $3.79M | $2.43M |
| Payables | $3.95M | $2.55M | $7.50M | $3.79M | $2.43M |
| Total Current Liabilities | $18.09M | $12.45M | $33.11M | $36.18M | $18.22M |
| -Current Capital Lease Obligation | $2.42M | $2.44M | $0.00 | $1.93M | $1.78M |
| Total Non-Current Liabilities | $1.36M | $1.90M | $0.00 | $14.11M | $16.04M |
| Capital Stock | $36,000.00 | $35,000.00 | – | – | – |
| Stockholders' Equity | $151.01M | $168.80M | $257.46M | $391.60M | $409.85M |
| Total Equity | $151.01M | $168.80M | $257.46M | $391.60M | $409.85M |
| -Long Term Capital Lease Obligation | $1.36M | $1.90M | $0.00 | $14.11M | $16.04M |
| Long Term Debt and Capital Lease Obligation | $1.36M | $1.90M | $0.00 | $14.11M | $16.04M |
| Total Liabilities | $19.45M | $14.34M | $33.11M | $50.30M | $34.26M |
| Other Equity Interests | – | – | $257.61M | $391.29M | $410.65M |
| Other Non-Current Assets | – | – | – | $256,000.00 | $256,000.00 |
| Investments and Advances | – | – | – | $35.47M | $27.03M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$17.05M | -$31.92M | -$32.56M | -$30.69M | -$38.64M |
| Net cash flow from continuing operations | -$17.05M | -$31.92M | -$32.56M | -$30.69M | -$38.64M |
| -Change in Prepaid Assets | -$837,000.00 | -$12.36M | $2.16M | -$1.54M | $1.08M |
| Free Cash Flow | -$17.05M | -$31.94M | -$32.58M | -$30.70M | -$38.68M |
| Beginning Cash Balance | $168.02M | $248.47M | $238.20M | $44.30M | $98.64M |
| Net Change in Cash | -$12.39M | -$80.45M | $10.27M | $65.54M | -$54.34M |
| Ending Cash Balance | $155.63M | $168.02M | $248.47M | $109.83M | $44.30M |
| Net Income from Continuing Operations | -$31.36M | -$33.37M | -$50.48M | -$41.86M | -$42.45M |
| Net Other Financing Charges | -$486,000.00 | -$235.07M | $7.85M | -$7.06M | -$52.11M |
| Net Common Stock Issuance | $0.00 | – | – | $0.00 | – |
| Net Cash Flow from Continuing Financing Activities | $4.66M | -$48.51M | $7.85M | -$7.06M | -$52.11M |
| Financing Cash Flow | $4.66M | -$48.51M | $7.85M | -$7.06M | -$52.11M |
| Net Investment Purchase and Sale | $0.00 | $0.00 | $35.00M | $103.29M | $36.44M |
| Net PPE Purchase and Sale | $0.00 | -$25,000.00 | -$17,000.00 | -$12,000.00 | -$39,000.00 |
| Net Cash Flow from Continuing Investing Activities | $0.00 | -$25,000.00 | $34.98M | $103.28M | $36.40M |
| Net cash flow from investing | $0.00 | -$25,000.00 | $34.98M | $103.28M | $36.40M |
| -Change in Other Current Liabilities | -$892,000.00 | -$93,000.00 | $0.00 | -$490,000.00 | -$479,000.00 |
| -Change in Payables and Accrued Expense | $6.14M | $5.24M | $4.15M | $3.87M | -$3.46M |
| Depreciation & Depletion & Amortization | $993,000.00 | $207,000.00 | $125,000.00 | $610,000.00 | $601,000.00 |
| Proceeds from Stock Option Exercised | $5.15M | – | – | $0.00 | – |
| Change in Working Capital | $4.42M | -$7.22M | $6.30M | $1.84M | -$2.85M |
No comments yet — be the first to weigh in on TRAX.
Sign in to join the discussion.